David B. Knowles
Keine laufenden Positionen mehr
Profil
David B.
Knowles served as Chairman at Absynth Biologics Ltd.
and Procarta Biosystems Ltd.
He was also the CSO & Director-Research & Development at Ligand UK Ltd., Piramed Ltd., and RiboTargets Ltd.
Prior to that, he was the Director-Molecular Biology at Smithkline Beecham Pharmaceuticals Ltd.
He holds a doctorate degree from Imperial College London, which he received in 1977.
Ehemalige bekannte Positionen von David B. Knowles
Unternehmen | Position | Ende |
---|---|---|
Procarta Biosystems Ltd.
Procarta Biosystems Ltd. Pharmaceuticals: MajorHealth Technology Procarta Biosystems Ltd. develops deoxyribonucleic acid based therapeutics and antibacterials. The company was founded by Michael McArthur and Mervyn Bibb on March 1, 2007 and is headquartered in Norwich, the United Kingdom. | Vorsitzender | 20.05.2016 |
Absynth Biologics Ltd.
Absynth Biologics Ltd. BiotechnologyHealth Technology Absynth Biologics Ltd. develops and manufactures immunological prophylaxis, novel vaccines and therapies. The company was founded by Simon J. Foster in 2007 and is headquartered in Alderley Edge, the United Kingdom. | Vorsitzender | - |
VERNALIS | Technik-/Wissenschafts-/F&E-Leiter | - |
RiboTargets Ltd. | Technik-/Wissenschafts-/F&E-Leiter | - |
Smithkline Beecham Pharmaceuticals Ltd. | Corporate Officer/Principal | - |
Ausbildung von David B. Knowles
Imperial College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 8 |
---|---|
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Piramed Ltd.
Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Commercial Services |
RiboTargets Ltd. | Health Technology |
American Society for Microbiology
American Society for Microbiology Miscellaneous Commercial ServicesCommercial Services The American Society for Microbiology (ASM) is the oldest and largest single life science membership organization in the world. The private company is based in Washington and has subsidiaries in the United States. ASM's membership has grown from 59 scientists in 1899 to more than 39,000 members today, with more than one third located outside. The members represent 26 disciplines of microbiological specialization plus a division for microbiology educators. | Commercial Services |
Wellcome Research Laboratories | |
Absynth Biologics Ltd.
Absynth Biologics Ltd. BiotechnologyHealth Technology Absynth Biologics Ltd. develops and manufactures immunological prophylaxis, novel vaccines and therapies. The company was founded by Simon J. Foster in 2007 and is headquartered in Alderley Edge, the United Kingdom. | Health Technology |
Procarta Biosystems Ltd.
Procarta Biosystems Ltd. Pharmaceuticals: MajorHealth Technology Procarta Biosystems Ltd. develops deoxyribonucleic acid based therapeutics and antibacterials. The company was founded by Michael McArthur and Mervyn Bibb on March 1, 2007 and is headquartered in Norwich, the United Kingdom. | Health Technology |
Smithkline Beecham Pharmaceuticals Ltd. |